Novavax (NASDAQ:NVAX) stock is taking off on Thursday after the company reached a settlement with global vaccine organization Gavi.This settlement has Novavax agreeing to pay up to $475 million to Gavi following a dispute over payments for its Covid-19 vaccine. The crux of the matter had to do with Gavi seeking a refund on a $700 million advance payment for vaccines it later chose not to order from Novavax.Novavax isn’t paying Gavi back all at once and will instead make payments through Dec. 31, 2028. This ...

A health worker prepares a dose of the Novavax vaccine as the Dutch Health Service Organization starts with the Novavax vaccination program on March 21, 2022 in The Hague, Netherlands.Novavax on Thursday said it will settle a bitter arbitration dispute with Gavi, a nongovernmental global vaccine organization, over a canceled Covid vaccine purchase agreement. Novavax could pay up to $475 million to the organization, but the total amount may be less if Gavi decides to order more shots from the cash-strapped c ...

It's official: The S&P 500 is in a bull market after reaching a new all-time high last month. The index actually has been in this positive market phase ever since it started recovering from its bear market low about 16 months ago -- and since bull markets generally last longer than bear markets, investors should have plenty of time to benefit from this one.How to get the most out of a bull market? By investing in stocks with solid growth prospects. That's because these environments usually support growth co ...

GAITHERSBURG, Md. and GENEVA, Feb. 22, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) and Gavi, the Vaccine Alliance (Gavi) today announced they have reached a settlement related to the 2021 Advance Purchase Agreement (APA) for Novavax's prototype COVID-19 vaccine (NVX-CoV2373). This agreement brings the pending arbitration related to the APA to a close. "Novavax is pleased to have reached this agreement with Gavi as it gives us the ability to continue to work together toward our shared mission of ensuri ...

GAITHERSBURG, Md., Feb. 20, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will report its fourth quarter and full year 2023 financial results and operational highlights at 8:30 a.m. Eastern Standard Time (EST) on Wednesday, February 28, 2024. Details of the event and replay are as follows:Conference call details: Date: February 28, 2024 Time: 8:30 a.m. U.S. EST URL to register phone: https://emportal.ink/3 ...

After a brutal three-year period that saw its shares collapse by 99%, any remaining longtime shareholders of Novavax (NVAX 5.13%) are doubtlessly eager for the biotech to finally step out of the shadows of its first "success" and launch its next winner, even if it means waiting as long as 10 years.Alas, that might not be enough time for this company to find its next big thing. In fact, it might not survive half that long. Here's why.Will it even be around?There is a strong possibility that Novavax won't eve ...

Novavax (NVAX -0.74%) stock may have made some millionaires back in 2020. It was the height of the coronavirus vaccine race, and investors were betting on this biotech company making it to the finish line. In that year, the stock soared 2,700%, and with a $40,000 investment in the shares, you could have become a millionaire -- if you locked in those gains.Since then, Novavax stock has tumbled more than 90% from its peak. The company disappointed investors by arriving at the vaccine finish line late and miss ...

Biotechnology firm Novavax (NASDAQ:NVAX)– which specializes in developing and commercializing next-generation vaccines — just announced a fresh round of job cuts. Earlier today, management said that it would reduce its global staff by about 12%. Now, NVAX stock is moving up on news of the Novavax layoffs. Tensions in the market also suggest that shares could jump even higher.According to Seeking Alpha, Novavax stated that its Board of Directors approved the Novavax layoffs in a meeting on Monday. In terms o ...

Like many of the biotechs pursuing coronavirus vaccine development, Novavax (NVAX -0.98%) has seen better days. Its shares are down by 96% over the past three years, and the company's remaining shareholders face fading hopes for a spontaneous revival.Nonetheless, while there are a few good arguments for why you should avoid investing, there's still one big reason to buy Novavax stock. Let's discuss the major point in its favor that might drive some to be interested in buying it, then follow up with a trio o ...

Novavax (NVAX -0.98%) shares have offered investors a roller coaster ride over the past few years. They soared more than 2,700% in early pandemic days as investors bet on the company's investigational vaccine -- then plummeted 98% from their peak as the vaccine entered the market late, missing out on the biggest revenue opportunity.Today, the company is generating sales from its vaccine, but less than anticipated, and that's forced Novavax to realign its cost base with the revenue opportunity. The biotech l ...